The chemist Mariano Barbacid announces that he does not know about an experimental treatment against pancreatic cancer in mice that he is investigating. The decision comes just a week after the journal of the United States National Academy of Sciences in which the results were presented due to “a relevant conflict of interest not declared at the time of presentation,” according to the journal’s editors. They were referring to the fact that Barbacid and other signatories did not report that they are co-owners with other partners of the company, founded to develop new therapies against pancreatic cancer. In a statement through a law firm, Barbacid announced this Tuesday that it will separate itself “completely” from Vega Oncotargets and from “the ownership of two patent applications belonging to the CNIO.”
